<DOC>
	<DOCNO>NCT02702778</DOCNO>
	<brief_summary>A four-week , randomize , control , open-label trial DR prednisone patient receive period 1 one three-night time dos treatment ( 4mg , 7mg 10mg ) two week follow period 2 treatment 15mg IR prednisone morning two week . Period 1 randomize open-label period 2 open label . Before enrollment randomization patient diagnosis responsiveness 15mg IR prednisone morning establish . 45 patient randomize , 15 patient treatment arm .</brief_summary>
	<brief_title>Delayed Release Prednisone PMR</brief_title>
	<detailed_description />
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>1 . Diagnosis PMR : 1 . All participant must meet Bird criterion ( 7 ) : 3 follow feature require make diagnosis . Bilateral shoulder pain/stiffness Onset symptom &lt; 2 week Initial Erythrocyte Sedimentation Rate ( ESR ) &gt; 40 mm/h Stiffness &gt; 1 h Age &gt; 65 year Depression and/or weight loss Bilateral upper arm tenderness 2 . All participant must PMR opinion PI 2 . Are 50 year old . 3 . No stable NSAID analgesic therapy least 7 day . 4 . Currently active disease define Creactive protein ( CRP ) least 5mg/L , ESR least 29mm one hour measure screen visit within previous week . 5 . Respond one week 15 mg IR prednisone one week washout ( patient worsens ) . Response measure : &gt; 70 % reduction morning stiffness severity end first week &gt; 80 % return morning stiffness severity second week ( screening procedure ) . This screening procedure also assess patient take one week &gt; 15 mg IR prednisone prior see investigator study , long informed consent obtain washout period inclusion criterion meet . 1 . Oral glucocorticoid treatment 1 week within previous month 2 . Parenteral glucocorticoid treatment within last month 3 . Pregnancy and/or lactation 4 . Inflammatory disease inflammatory bowel disease , colitis , asthma , rheumatoid arthritis 5 . Coexistent giant cell arteritis ; patient headache , visual symptom jaw claudication suggestive giant cell arteritis include study 6 . Other autoimmune disease 7 . Synovitis polymyositis 8 . Positive Cyclic Citrullinated Peptide Antibodies ( CCP ) 9 . Muscle weak elevate creatinine phosphokinase ( CPK ) 10 . Cancer ( patient history basal cell carcinoma cancerfree &gt; 5 year allow ) 11 . Severe active infection include herpes viral bacterial infection ( ) , treatment antibiotic within past 6 week history tuberculosis 12 . Significant renal disease ( creatinine great than150 Âµmol/L ) 13 . Significant hepatic impairment ( ALT/AST great twice upper limit normal ) 14 . Immunization live vaccine within 8 week first administration study drug plan immunization live vaccine within 2 week last administration study drug . 15 . Use systemic glucocorticoid include inhalant screen treatment phase study ; chronic intranasal ophthalmic corticosteroid allow . 16 . Participation clinical trial investigational drug within past 30 day 17 . Working nighttime shift employee 18 . Jet lag ( i.e . airplane travel ) 19 . Unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Polymyalgia Rheumatica ( PMR )</keyword>
</DOC>